We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTI1.L Regulatory News (TI1)

  • There is currently no data for TI1

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Compulsory Share Redemption Update

2 Mar 2023 07:00

RNS Number : 5801R
Trian Investors 1 Limited
02 March 2023
 

TRIAN INVESTORS 1 LIMITED(the "Company")

 

In-specie Share Distribution and associated Compulsory Share Redemption

2 March 2023

 

Further to the announcement on 17 February 2023, the Board is pleased to announce the details of an in-specie distribution by the Company of the Unilever plc ("ULVR") shares (the "Share Distribution"), which were distributed from Trian Investors 1, L.P. (the "Investment Partnership") to the Company on 16 February 2023 which is to be effected by way of a compulsory partial redemption of the ordinary shares in issue in the capital of the Company (the "Ordinary Shares") (the "Share Redemption").

Share Distribution

The Share Distribution will be applied pro rata to an investor's holding of Ordinary Shares on the register at the close of business on the Record Date, being 10 March 2023 and will be effected through the Share Redemption, as described below. The Share Distribution will be undertaken at a ratio of 0.0430749929 ULVR ordinary shares for each Ordinary Share (the "Distribution Ratio") in issue as at the Record Date.

Fractional entitlements to ULVR shares pursuant to the Share Distribution will not be distributed to shareholders. Entitlements to ULVR shares will be rounded down to the nearest whole number with fractional entitlements being aggregated and sold in the market. The net cash proceeds of such sale are expected to be distributed to relevant shareholders via CREST shortly after entitlements to ULVR shares have been distributed to shareholders in consideration for the Share Redemption.

Share Redemption

The Share Distribution will be effected by way of the Share Redemption. As at 16 February 2023 the ULVR shares being distributed represented approximately 94.092563 per cent. of the Company's net asset value and therefore it is proposed that 94.092563 per cent. of each investor's holding of Ordinary Shares will be compulsorily redeemed (rounded down to the nearest whole share).

All Ordinary Shares that are redeemed will be cancelled with effect from the Record Date and accordingly will thereafter be incapable of transfer by Shareholders or re-issue by the Company.

Based on the ULVR share price as at the close of business on 16 February 2023, being the date on which the ULVR shares were distributed from the Investment Partnership, the redemption amount per Ordinary Share to be compulsorily redeemed by the Company pursuant to the Share Redemption equates to 193.69 pence per Ordinary Share (equating to an aggregate amount of £42,760,178.40 in respect of 22,076,289 Ordinary Shares, with the investors receiving such amount by the Share Distribution and any cash payment in respect of fractional entitlements to which shareholders are entitled).

The existing Ordinary Shares will be disabled in CREST after close of business on the Record Date and the existing ISIN number, GG00BKQN9F08 (the "Old ISIN") will expire. The new ISIN number, GG00BQKR7233 in respect of the remaining Ordinary Shares which have not been compulsorily redeemed (the "New ISIN") will be enabled and available for transfer from 8.00 a.m. on 13 March 2023. The share price TIDM "TI1.L" will remain unchanged. CREST will automatically transform any open transactions as at the Record Date into the New ISIN.

ULVR dividends

Shareholders should note that, in the event they retain the ULVR shares distributed by way of the Share Distribution, they will be entitled (directly) to any dividends declared by ULVR with a record date post the Record Date of 10 March 2023. For the avoidance of doubt, the Company is entitled to the quarterly interim ULVR dividend which was declared on 9 February 2023 and which is payable on 21 March 2023 to ULVR shareholders on the ULVR register as of 24 February 2023.

Expected Timetable

Record date for entitlement for Share Redemption and Share Distribution

Last day of trading in TI1 ordinary Shares under the Old ISIN

 

10 March 2023

Ex date for entitlement for Share Redemption and Share Distribution

New ISIN numbers enabled

Trading in TI1 Ordinary Shares under the New ISIN commences

ULVR shares credited to shareholders in CREST

 

13 March 2023

Cash payment (via CREST) in respect of fractional entitlements

By 17 March 2023

 

Following the completion of the Share Distribution and Share Redemption, the Board will commence the process to wind-up the Company. The Board expects that the Company will publish a circular to shareholders relating to the winding up of the Company shortly following the completion of the Share Redemption and Share Distribution. Further details of the liquidation will be announced in due course.

 

Net Asset Value

 

As at the date of this announcement, the Company has 23,462,338 Ordinary Shares in issue. Subsequent to the Share Redemption as outlined above, it is expected that the total number of Ordinary Shares in issue will be 1,386,048, each with equal voting rights.

 

As at 16 February 2023, being the date on which the ULVR shares were distributed from the Investment Partnership, the Net Asset Value of the Company was £45.44 million, or 193.69 pence per Ordinary Share. For illustrative purposes only, the pro-forma Net Asset Value of the Company as at 16 February 2023 reflecting the proposed Share Distribution and Share Redemption as if they had been effected on that same date, would have been £2.68 million, or 193.69 pence per Ordinary Share.

 

As previously announced, the Board of the Company, in consultation with the Company's advisors and Trian Investors Management, LLC, have made provisions for estimated redemption and wind-up expenses.. In addition, as a consequence of the distribution of the ULVR shares, full provision has been made in the Company's NAV as at 16 February 2023 for all management fees payable to the Investment Manager up to 31 December 2023.

 

LEI: 213800UQPHIQI5SPNG39

 

Terms not defined in this announcement shall have the meaning defined in the Company's prospectus dated 21 September 2018.

 

For further information, please contact:

 

Numis Securities Limited

(Corporate Broker) 

+44 (0)20 7260 1000

David Benda

Nathan Brown

Vicki Paine

 

Ocorian Administration (Guernsey) Limited(Administrator and Company Secretary)+44 (0)1481 742 742Chezi Hanford

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFFDVSILIIV
Date   Source Headline
26th Apr 20234:22 pmRNSNotice of EGM Results
26th Apr 20234:21 pmRNSNotice of AGM Results
26th Apr 20237:30 amRNSSuspension - Trian Investors 1 Limited
17th Apr 20235:03 pmRNSNet Asset Value as at 31 March 2023
6th Apr 20232:55 pmRNSHolding(s) in Company
3rd Apr 20237:00 amRNSTotal Voting Rights
24th Mar 20237:01 amRNSNotice of EGM
24th Mar 20237:00 amRNSNotice of AGM
22nd Mar 20237:00 amRNSDirector/PDMR Shareholding
17th Mar 20237:00 amRNSAnnual Report to 31 December 2022
16th Mar 202312:08 pmRNSNAV as at 28 February 2023 and as at 13 March 2023
14th Mar 20232:43 pmRNSTotal Voting Rights
2nd Mar 20237:00 amRNSCompulsory Share Redemption Update
22nd Feb 20232:53 pmRNSNet Asset Value as at 16 February 2023
22nd Feb 20232:37 pmRNSNet Asset Value as at 31 January 2023
17th Feb 20237:00 amRNSCompulsory Share Redemption Update
1st Feb 20237:00 amRNSTotal Voting Rights
19th Jan 20237:00 amRNSIn-specie Distribution & Complusory Redemption
19th Jan 20237:00 amRNSNet Asset Value as at 6 January 2023
9th Jan 20236:01 pmRNSNet Asset Value as at 31 December 2022
9th Jan 20237:00 amRNSCompulsory Share Redemption Update
14th Dec 20225:26 pmRNSNet Asset Value as at 30 November 2022
11th Nov 20224:34 pmRNSNet Asset Value as at 31 October 2022
26th Oct 20225:16 pmRNSReplacement - Net Asset Value(s)
25th Oct 20224:16 pmRNSNet Asset Value as at 30 September 2022
24th Oct 20228:51 amRNSHolding(s) in Company
15th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSNet Asset Value as at 31 August 2022
6th Sep 202210:42 amRNSHolding(s) in Company
2nd Sep 20227:00 amRNSCompulsory Share Redemption by 30 June 2023
15th Aug 20225:30 pmRNSChanges to Director Roles and Responsibilities
12th Aug 20227:00 amRNSNet Asset Value as at 31 July 2022
8th Aug 20227:00 amRNSResult of EGM
8th Aug 20227:00 amRNSDirector Changes
8th Aug 20227:00 amRNSResult of AGM
11th Jul 20222:01 pmRNSNotice of AGM
11th Jul 20222:00 pmRNSNotice of Requisitioned EGM
11th Jul 20227:00 amRNSNet Asset Value as at 30 June 2022
1st Jul 20227:00 amRNSTotal Voting Rights
21st Jun 20227:00 amRNSTransaction in Own Shares
20th Jun 20223:56 pmRNSReceipt of Requisition Notice
15th Jun 20227:00 amRNSNet Asset Value as at 31 May 2022
31st May 20228:00 amRNSInvestment in Unilever
6th May 20226:00 pmRNSNet Asset Value as at 30 April 2022
14th Apr 20227:01 amRNSDirector Appointment
14th Apr 20227:00 amRNSAnnual Report to 31 December 2021
13th Apr 20225:53 pmRNSNet Asset Value as at 31 March 2022
29th Mar 202210:11 amRNSNew US$100m Revolving Credit Facility
16th Mar 20224:53 pmRNSNet Asset Value as at 28 February 2022
1st Mar 20227:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.